MTRNR2L12: A Potential Drug Target and Biomarker (G100463498)

Target Name: MTRNR2L12

NCBI ID: G100463498

MTRNR2L12

MTRNR2L12: A Potential Drug Target and Biomarker

MTRNR2L12, also known as SIRT3, is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and metabolic disorders. Its unique structure and function have made it an attractive target for researchers to investigate, and recent studies have shed light on its potential role in these fields.

The MTRNR2L12 molecule is a small non-coding RNA molecule that is expressed in most tissues and cells of the body. It has a unique structure, with a length of approximately 240 nucleotides and a 19-amino acid tail. The molecule has a single exon that is predominantly expressed in the brain and central nervous system (CNS), and it is also expressed in other tissues, including the heart, muscle, and liver.

One of the unique features of MTRNR2L12 is its ability to interact with various protein molecules, including nuclear factor kappa B (NFkB), which is a transcription factor that plays a role in regulating gene expression and cell signaling. This interaction between MTRNR2L12 and NFkB suggests that it may be a useful biomarker for evaluating the activity of drugs that target NFkB signaling pathways.

In addition to its potential as a drug target, MTRNR2L12 has also been identified as a potential biomarker for a variety of diseases. For example, studies have shown that MTRNR2L12 is downregulated in various tissues and cells of the brain, including those affected by neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. This suggests that MTRNR2L12 may be a useful biomarker for evaluating the effectiveness of neurodegenerative drugs.

Another potential application of MTRNR2L12 as a drug target is its role in the regulation of inflammation. MTRNR2L12 has been shown to play a role in the regulation of various immune cells, including natural killer cells and T cells, which are important for fighting off infections and cancer. Additionally, MTRNR2L12 has been shown to regulate the production of pro-inflammatory cytokines, which can contribute to inflammation and tissue damage. This suggests that MTRNR2L12 may be a useful target for drugs that are designed to prevent or alleviate inflammation.

The MTRNR2L12 molecule has also been shown to play a role in the regulation of cellular processes that are important for maintaining cellular health and longevity. For example, studies have shown that MTRNR2L12 is involved in the regulation of cell apoptosis, which is the process by which cells are programmed to die when they have reached a certain size or are no longer needed. Additionally, MTRNR2L12 has been shown to play a role in the regulation of cellular signaling pathways that are important for cell growth, differentiation, and survival.

Given its unique structure and function, MTRNR2L12 is an attractive target for researchers to investigate as a potential drug target and biomarker. Its ability to interact with various protein molecules, including NFkB, suggests that it may be a useful target for drugs that target NFkB signaling pathways. Its potential as a biomarker for neurodegenerative diseases and its role in the regulation of inflammation and cellular processes suggest that it may be a valuable tool for the development of new treatments for a variety of diseases.

In conclusion, MTRNR2L12 is a small non-coding RNA molecule that has a unique structure and function. Its potential as a drug target and biomarker makes it an attractive target for researchers to investigate and develop new treatments for a variety of diseases. Further studies are needed to fully understand the role of MTRNR2L12 in

Protein Name: MT-RNR2 Like 12 (pseudogene)

The "MTRNR2L12 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MTRNR2L12 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets